Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer

Oncogene

Volumn 35, Issue 6, 2016, Pages 691-701

  Seviour, E G ^a   Sehgal, V ^a   Lu, Y ^a   Luo, Z ^a   Moss, T ^a   Zhang, F ^a   Hill, S M ^b   Liu, W ^c   Maiti, S N ^c   Cooper, L ^c   Azencot, R ^d   Lopez Berestein, G ^c   Rodriguez Aguayo, C ^c   Roopaimoole, R ^c   Pecot, C ^c   Sood, A K ^c   Mukherjee, S ^b   Gray, J W ^e   Mills, G B ^a   Ram, P T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UTMDACC   (United States)

^d University of Houston   (United States)

^e Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; COLLAGEN TYPE 1; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLCHOLINE NANOPARTICLE; ETOPOSIDE; FIBRONECTIN; LAMININ; MICRORNA; MICRORNA 124; MICRORNA 18A; MICRORNA 365; MICRORNA 506; MYC PROTEIN; NANOPARTICLE; PROTEIN P27; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MIRN124 MICRORNA, HUMAN; PHOSPHOPROTEIN; TRANSCRIPTOME;

3' UNTRANSLATED REGION; ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREAST CANCER; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FUNCTIONAL PROTEOMICS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; WESTERN BLOTTING; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; ONCOGENE MYC; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTEOMICS; TUMOR CELL CULTURE;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; PROTEOMICS; RETINOBLASTOMA PROTEIN; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84958046162     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.469     Document Type: Article

References (51)

1. Evan G. Cancer. Taking a back door to target Myc. Science 2012; 335: 293-294.
2. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999; 18: 2988-2996.
3. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 1999; 18: 2934-2941.
4. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012; 18: 5546-5553.
5. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
6. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000; 97: 3260-3265.
7. Shiio Y, Donohoe S, Yi EC, Goodlett DR, Aebersold R, Eisenman RN. Quantitative proteomic analysis of Myc oncoprotein function. EMBO J 2002; 21: 5088-5096.
8. Chandramohan V, Mineva ND, Burke B, Jeay S, Wu M, Shen J et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J Cell Biochem 2008; 104: 2091-2106.
9. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 2001; 20: 1688-1702.
10. DeGregori J. The Rb network. J Cell Sci 2004; 117(Pt 16): 3411-3413.
11. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
12. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012; 19: 586-593.
13. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172-1187.
14. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002; 30: 363-364.
15. Szymanski M, Barciszewski J. Regulation by RNA. Int Rev Cytol 2003; 231: 197-258.
16. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002; 9: 1327-1333.
17. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006; 13: 1776-1788.
18. Hoyt DG, Rusnak JM, Mannix RJ, Modzelewski RA, Johnson CS, Lazo JS. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 1996; 56: 4146-4149.
19. Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98: 1897-1903.
20. Zhang H, Ozaki I, Mizuta T, Matsuhashi S, Yoshimura T, Hisatomi A et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 2002; 95: 896-906.
21. Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang J et al. miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis 2013; 34: 415-425.
22. Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med 2014; 20: 360-367.
23. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14: 2690-2695.
24. Xu XL, Jiang YH, Feng JG, Su D, Chen PC, Mao WM. MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma. Ann Thorac Surg 2014; 97: 1037-1045.
25. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012; 109: 9545-9550.
26. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007; 3: 166-173.
27. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA 2006; 103: 17337-17342.
28. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 2008; 105: 1608-1613.
29. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581.
30. Cao X, Pfaff SL, Gage FH. A functional study of miR-124 in the developing neural tube. Genes Dev 2007; 21: 531-536.
31. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett 2011; 585: 187-192.
32. Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y et al. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One 2013; 8: e70300.
33. Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013; 32: 4130-4138.
34. Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT et al. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013; 34: 713-722.
35. Lang Q, Ling C. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun 2012; 426: 247-252.
36. Xia H, Cheung WK, Ng SS, Jiang X, Jiang S, Sze J et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012; 287: 9962-9971.
37. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278-289.
38. Xia J, Wu Z, Yu C, He W, Zheng H, He Y et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol 2012; 227: 470-480.
39. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013; 73: 3913-3926.
40. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle 2006; 5: 2103-2109.
41. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 2014; 5: 3887.
42. Kang S, Zhao Y, Hu K, Xu C, Wang L, Liu J et al. miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway. Prostate 2014; 74: 1095-1106.
43. Li Y, Zhang Z, Liu X, Huang T, He W, Shen Y et al. miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3. Mol Cell Biochem 2013; 388: 219-231.
44. Lu Y, Yue X, Cui Y, Zhang J, Wang K. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun 2013; 441: 873-879.
45. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013; 4: 2427.
46. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S et al. Kinome siRNAphosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011; 30: 4567-4577.
47. Cancer Genome Atlas N, Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
48. Cancer Genome Atlas N, Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
49. Cancer Genome Atlas Research N, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
50. Cancer Genome Atlas Research N, Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
51. Cancer Genome Atlas Research N, Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.